Audit: QRS - L-Methylfolate for Health & Longevity

Audit conducted on 28/08/2026 12:10 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells trace to ER Therapeutic Protocol (lines 338–342); time cells to ER Practical Considerations (line 395) and Monitoring Protocol (line 423); benefits/risks to ER tier headings; gates to ER lines 289–316; markers to ER table (lines 427–435).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	At-A-Glance carries the ER Conclusion’s hedges (“Clinical evidence is thinner”, “resting mainly on company-funded depression trials”); marker_9_target retains “No established target”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication qualifiers (“until replaced”, “unless the oncology team directs otherwise”) preserved at their ER strength; no tier promotion or demotion.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications; benefits from Expected Benefits; risks from Potential Risks & Side Effects; markers from Monitoring Protocol. No cross-category migration.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only brand names Metafolin and Quatrefolic appear (line 581), matching the same ER contraindication bullet (ER line 315). No PMIDs, NCT IDs, or expert names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS body.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, evidence-weighted register, including its scepticism about the industry-funded depression base.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Actionable dose tiers and measurable targets are given without overselling; limits are stated plainly.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as what protocols and trials do, not as instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; cadence and gates use descriptive noun phrases (“Baseline panel before starting”, “Untreated or unconfirmed vitamin B12 deficiency”).
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of “should”, “must”, “recommend”, or “advise” in document voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained only where they are the ER’s own biomarker or drug-class names; MMA is expanded at first use (line 703).
2.8	Information is presented in a concise and very compact manner	🟢	All list items reduced to key facts; mechanisms, effect sizes, and citations stripped throughout.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional target ranges (homocysteine 5–8 µmol/L, B12 500–900 pg/mL) rather than conventional laboratory cut-offs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine-marker baseline panel and repeat testing schedule assume a willing, effort-tolerant reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified general-population framing; assumes access to laboratory testing and genotype awareness.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The B12-masking hazard is elevated to the At-A-Glance headline and to the first contraindication, matching the ER’s weighting for self-directed supplement users.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” used in the title and header; no occurrence of “anti-aging”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Uses “adverse events”, “hypersensitivity reaction”, “contraindication”; plain-language renderings in At-A-Glance mirror the ER Conclusion’s own wording.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings verified verbatim against the template: lines 446, 491, 537, 569, 589, 615, 641, 645–647, 782, and the tier labels in the benefits and risks lists.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 distinct template variable names present, with marker_#* expanded to nine rows and qualitative_item# to five items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Lines 16–410 are byte-identical to the template apart from page_title; the website=”evidence_review”, website=”audit”, and website=”full_review” spans and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that maps to a QRS field is empty. The High risk tier is handled under the more specific rule 13.5, which mandates display:none rather than empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Maintenance dose”, “Homocysteine-directed dose”, “Psychiatric adjunct dose” match ER lines 338–342 verbatim; caution items reuse the ER’s bold interaction labels; marker names match the ER table’s biomarker column.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Every label maps to an ER bold label or ER table row; the three time-to-effect labels use the ER’s own terms from the single “Time to effect” bullet (ER line 395).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; tiers conveyed by bold labels plus the .benefits and .risks CSS palettes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than transcribed: mechanisms, magnitudes, citations and mitigation clauses are stripped from the ER source, and the print CSS (A4, 12mm padding) is unmodified from the template.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment spanning lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the preamble text on line 2 sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are echoed in the body except the intended header date and model name.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon requiring YAML quoting. All other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: l_methylfolate_2026-0828-0001_Opus_ER.md, matching the ER’s own filename frontmatter field.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0828-1152, correctly formatted.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: l_methylfolate_2026-0828-0001_Opus_QRS.html, matching the actual file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eight keys plus git_user and git_issue; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “L-Methylfolate for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “L-Methylfolate for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/28/2026”, correctly derived from qrs_creation_date: 2026-0828-1152.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” list is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all three Conclusion paragraphs (ER lines 469–473) into identity, biochemical case, clinical limits, and the governing hazard.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“ready-to-use form of vitamin B9” → ER line 469; “raises folate stores faster” and “lowers the amino acid marker” → ER line 469; “company-funded depression trials” → ER line 471; “hide a nerve-damaging deficiency” → ER line 473.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Homocysteine rendered as “the amino acid marker tied to blood vessel and brain ageing”; only the everyday vitamin designations B9 and B12 appear.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Trials referenced only generically as “head-to-head trials” and “company-funded depression trials”.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates or statistics present.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All four items map to the “Populations who should avoid L-Methylfolate” list at ER lines 313–316.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete 4-of-4 coverage: B12 deficiency, methotrexate/fluoropyrimidine chemotherapy, folate-salt hypersensitivity, unmonitorable phenytoin.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Four discrete <li> elements at lines 572–584 inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Leading “Anyone with” / “Patients receiving” / “People with” stems dropped; no dashes or trailing clauses; no mechanism or citation retained.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Threshold “(B12 below 200 pg/mL or raised methylmalonic acid)” and the conditions “until replaced”, “for malignancy, unless the oncology team directs otherwise”, “whose drug levels cannot be monitored” all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names four such populations, and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map to the bulleted interaction list at ER lines 289–309.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine of eleven ER interaction bullets carried; methotrexate and fluorouracil/capecitabine correctly omitted because they are covered by the chemotherapy contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine discrete <li> elements at lines 592–605 inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “— caution:” / “— monitor:” severity tags and every mechanism and Mitigation sentence are stripped; only the bold label remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Acid-suppressant list “(omeprazole, esomeprazole, famotidine, cimetidine)” and the methylation-supplement list “(betaine, choline, S-adenosylmethionine, creatine, high-dose niacin, active vitamin B6)” both retained in full.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction list uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eleven such interactions, and the section is correctly populated rather than left empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol dose bullets at lines 338, 340 and 342.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three dose tiers are the ER’s only actionable dosing decisions; the remaining bullets are competing positions, timing notes and modifiers rather than primary actions.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct actionable aspects exist and all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Nine of nine fields populated: labels verbatim from ER bold labels, values “400–1,000 µg daily” / “1–5 mg daily” / “15 mg daily”, subs condensed from the same ER bullets.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Depression scores, red cell folate and homocysteine are drawn from the ER “Time to effect” bullet at line 395; the fourth aspect, plasma folate, is folded into time_2_sub.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER benefit tiers: depression response and red cell folate rise are both High, homocysteine lowering is Medium.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies four distinct time-to-effect aspects and all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Nine of nine fields populated: “30–60 days”, “Beyond 24 weeks” and “4–8 weeks” with supporting subs from ER lines 395 and 423.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight benefit items map to the ER tier headings at lines 151–199.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 539–562, in tier order.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Every Magnitude: paragraph and the ⚠️ Conflicted markers are stripped; “Through Methyl-Cycle Support” is trimmed from the brain-atrophy heading as mechanistic detail.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven risk items map to the ER tier headings at lines 229–269.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 617–635.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Odds ratios, the methyl-trapping mechanism, sponsor attribution and the ⚠️ Conflicted marker are all stripped; only the ER headings remain.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No risk reaches High” (line 225) and risks_high is correctly set to style="display: none" with empty content at line 617.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Every row’s marker, target and rationale trace to the ER biomarker table at lines 425–435.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers present: homocysteine, red cell folate, serum folate, serum B12, MMA, CBC with MCV, hsCRP, eGFR, 25-hydroxyvitamin D.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 772–776 condense ER lines 421–423: baseline panel, 8–12 week recheck, 6–12 month maintenance interval, annual or six-monthly B12, and the 8/12-week symptom review at 15 mg.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items map to the qualitative marker bullets at ER lines 439–443.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Five of five carried: depressive symptom burden, afternoon energy, cognitive clarity, sleep onset and continuity, and early restlessness or palpitations.

Issues 28/08/2026 12:10

Pass rate 100.00%. No issues found.

Issues 28/08/2026 12:05

1. 4.2 / 4.3 — Interaction label paraphrased: The Key Interactions item at line 601 reads “Additive methylation supplements (betaine, choline, S-adenosylmethionine, creatine, high-dose niacin, active vitamin B6)”, paraphrasing the ER’s bold label “Supplements with additive homocysteine or methylation effects” (ER line 305) and dropping its homocysteine dimension.

Fixes 28/08/2026 12:05

1. 4.2 / 4.3 — Interaction label restored verbatim: Replaced the paraphrased Key Interactions label “Additive methylation supplements” with the ER’s verbatim bold label “Supplements with additive homocysteine or methylation effects”, keeping the parenthetical example list intact.

Issues 28/08/2026 11:59

1. 4.5 — Sheet exceeds one-A4 budget: The Monitoring card carries all nine ER biomarkers with full-length “why” text plus a 14-word prose target cell for marker 9 (lines 759-762), and Qualitative Assessment carries five full-length ER sentences (lines 786-816); the stacked content is roughly 1.8 A4 pages rather than one.
2. 12.3 — Mechanistic clause in benefit: [benefits_low] (line 553) reads “Slower brain atrophy and cognitive decline through methyl-cycle support”; the trailing mechanistic clause is banned by 12.3, which requires just the key fact.

Fixes 28/08/2026 11:59

1. 12.3 — Mechanistic clause stripped from benefit: [benefits_low] changed from “Slower brain atrophy and cognitive decline through methyl-cycle support” to “Slower brain atrophy and cognitive decline”, leaving just the key fact.
2. 4.5 — Monitoring target cell condensed: [marker_9_target] shortened from “No established target specific to folate status; track change from the individual’s own baseline” to “No established target; track change from baseline”.
3. 4.5 — Qualitative Assessment condensed: All five [qualitative_item_#] entries were trimmed of ER connective prose (e.g. item 3 from “…and the sense of mental fatigue late in the day” to “…late-day mental fatigue”), cutting each from two rendered lines toward one.
4. 4.5 — Decision-gate items condensed: The first [stop_items] entry was tightened to “Untreated or unconfirmed vitamin B12 deficiency (B12 below 200 pg/mL or raised methylmalonic acid), until replaced” and the methylation-supplement [caution_items] entry to “Additive methylation supplements (…)”, both keeping their parenthetical qualifiers.
5. 4.5 — Monitoring rationale condensed: [marker_7_why] shortened from “Identifies the inflammatory phenotype that responded best in the depression trials” to “The inflammatory phenotype that responded best in the depression trials”.